DataMEDS AI, Inc. (NASDAQ: MEDS) announced its financial results for the third quarter ended September 30, 2026, reporting a net income of $10.54 million and a net profit per share of $2.72. The company also disclosed that it has regained full compliance with Nasdaq listing standards.
For the three months ended September 30, 2026, the company recorded net revenues of $2.67 million. This figure represents a 50% increase from the $1.8 million reported in the second quarter of 2026. The press release attributes this growth primarily to the Corexa Pharmacy drug dispensing segment.
Net profit from operations was $10.54 million in the third quarter of 2026, a significant improvement compared to a net operating loss of $34.32 million in the same period in 2025. The company attributes this shift to the extinguishment of debt and liabilities related to litigation, as well as a reduction in management compensation and general and administrative expenses.
In terms of business updates, DataMEDS AI launched the Health Lives Here mobile application in partnership with the NFL Alumni Health marketing platform. This app is designed to facilitate the dispensing of FDA-approved GLP-1 medications and the medical food Forzet for patients.
The company also secured an exclusive license to the REBOOT GLP-1 patient management platform in October 2026. Additionally, Corexa Pharmacy began dispensing compounded peptides in November 2026 under the FDA's Enforcement Discretion Policy. The company signed a non-binding memorandum of understanding with a Florida-based HMO in November 2026 to deploy the Health Lives Here app to over 25,000 members.
On the acquisition front, DataMEDS AI acquired Helomics Corporation, a cancer diagnostics laboratory, in September 2026. This acquisition, combined with Humana's Medicaid coverage for the proprietary ChemoFx Assay, is intended to create an incremental proprietary revenue stream. The company also noted that Helomics possesses a biobank of over 70,000 primary tumor biopsies.
